Moreover, in contrast to previous reports in HBC73–75, PIK3CA and other PI3Ks activating AKT as well as AKT1 and AKT3 were downregulated or not differentially expressed in tumours, suggesting that subtypes evaluated here are not likely to respond to therapies targeting PI3Ks and AKT inhibitors. This evidence concerns the gene PIK3CA and neoplasm.